Practical Patient Care’s Post

View organization page for Practical Patient Care, graphic

1,850 followers

Exciting news in neuroscience diagnostics! Fujirebio Diagnostics, Inc. has launched the Lumipulse G GFAP assay in the US, a groundbreaking tool for researchers studying neurological conditions. This fully automated Chemiluminescent Enzyme Immunoassay (CLEIA) test quantitatively measures glial fibrillary acidic protein (GFAP) in human plasma and serum in just 35 minutes. Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc., states: "We continue our engagement in biomarker-based testing for neurological diseases with the Lumipulse G GFAP, affirming our commitment to play an essential partnering role in both research and clinical routine." This launch further solidifies Fujirebio's position as a leader in neuro biomarker testing, following their 2023 introductions of NfL and pTau 217 assays. https://lnkd.in/euNv5Sat 📰 Stay ahead of the curve by following Practical Patient Care on LinkedIn for more industry news and insights. #PracticalPatientCare #Neuroscience #Diagnostics #MedicalInnovation

  • Fujirebio launches the Lumipulse G GFAP assay.

To view or add a comment, sign in

Explore topics